- Home
- Products
- Customized ADCs
- SOST
- Anti-SOST (Romosozumab)-MC-MMAF ADC
Anti-SOST (Romosozumab)-MC-MMAF ADC (CAT#: ADC-W-1774)
This ADC product is comprised of an anti-SOST monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- SOST
- Alternative Names
- SOST; sclerostin; sclerosteosis; VBCH;
- Target Entrez Gene ID
- 50964
- Target UniProt ID
- Q9BQB4
- Overview
- Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease.
- Overview
- Humanized Anti-SOST IgG2-kappa antibody, Romosozumab
- Generic name
- Romosozumab
- Host animal
- Mouse
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-PDCD1-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1697)
- Anti-CD4 (Tregalizumab)-SPDB-DM4 ADC (CAT#: ADC-W-873)
- Anti-CD3E (Foralumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-839)
- Anti-IGF1R (Cixutumumab)-MC-MMAF ADC (CAT#: ADC-W-1246)
- Anti-ERBB2 (trastuzumab)-Aminocaproyl-MMAF ADC (CAT#: ADC-W-635)
- Anti-Phosphatidylserine (Sevirumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1987)
- Anti-CD56 (clone huN901)-SPDB-[3H]DM1 ADC (CAT#: ADC-W-599)
- Anti-HCMV (Regavirumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2107)
- Anti-SOST (Romosozumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1777)
- Anti-EPCAM (Adecatumumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1073)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1774. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-1777 | Anti-SOST (Romosozumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-1776 | Anti-SOST (Romosozumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-1767 | Anti-SOST (Blosozumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-1775 | Anti-SOST (Romosozumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-1768 | Anti-SOST (Blosozumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
CAT# | Product Name | Linker | Payload |
ADC-W-515 | Anti-EGFR (ABT-806)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-537 | Anti-TPBG-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-517 | Anti-TM4SF1 ( clone v1.10)-Mc-LP2 ADC | Mc (maleimidocaproyl) | LP2 (chemical name mc-3377) |
ADC-W-493 | Anti-CD19 (clone huB4)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
CAT# | Product Name | Linker | Payload |
ADC-W-2544 | Anti-CD44 (Bivatuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2550 | Anti-CD74-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2585 | Anti-EGFR (Zalutumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2591 | Anti-EGFR (Cetuximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.